NEW YORK, Feb. 29, 2016 -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system ("CNS") disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the Cowen and Company 36th Annual Health Care Conference in Boston, MA. The presentation is scheduled for Tuesday, March 8th, 2016 at 10:00 am EST.
The live and archived webcast can be accessed under "Events & Presentations" in the Investor Relations section of the Company's website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software.
About Intra-Cellular Therapies
Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in dementia, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia and bipolar depression. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.
CONTACT: Intra-Cellular Therapies, Inc. Juan Sanchez, M.D. Vice President, Corporate Communications and Investor Relations 646-440-9333 Burns McClellan, Inc. Lisa Burns Justin Jackson (Media) [email protected] 212-213-0006


SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Instagram Outage Disrupts Thousands of U.S. Users
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 



